Sponsored by Pfizer
Date: Wednesday 10 April
Time: 1030 – 1145
Room: M1 & M2
The management of psoriatic arthritis (PsA) has undergone a renaissance over recent years with a better understanding of critical pathways in the pathogenesis of PsA and the development of targeted therapies that effectively inhibit these pathways with dramatic efficacy on all involved domains including peripheral and axial disease, dactylitis, enthesitis , skin and nail disease. Inhibition of radiologic progression has also been demonstrated with many of these therapies.
Inhibitors of Janus kinases (JAK) have made an important impact in the management of rheumatoid arthritis and now attention has turned to their efficacy and safety in PsA.
This symposium will highlight the unmet needs in PsA and the latest developments in both biomarkers and outcome measures. The efficacy and safety results will be presented from the pivotal registration trials of tofacitinib in patients with PsA that are traditional DMARD inadequate responders and those that are biologic DMARD non-responders.
The symposium will end with a panel Q and A session which will allow the audience to quiz the speakers.
|Tuesday 9 April 2019|
|1030 – 1035||Introduction||Chair|
|1035 – 1100||Unmet needs in PsA – biomarkers, outcome measures||Prof. Oliver FitzGerald|
|1100 – 1130||OPAL Broaden & Beyond key takeout …. What this means in Practice?||Assoc. Prof Peter Nash|
|1130 – 1140||XELJANZ PsA Safety Data and OPAL Balance||Prof. Oliver FitzGerald|
|1140 – 1145||Q&A||Assoc. Prof Peter Nash and/or Prof. Oliver FitzGerald|